von Hugo R, Hafter R, Hiller K F, Lochmüller H, Selbmann H K, Graeff H
Geburtshilfe Frauenheilkd. 1981 Mar;41(3):179-83. doi: 10.1055/s-2008-1037350.
Patients treated for gynaecological cancer by combined external irradiation and intravaginal radium application participated in two randomized, controlled, and prospective trials. In the first trial the incidence of deep vein thrombosis (DVT) diagnosed by the 125I-fibrinogen test was 43% in the control group. The injection of 7,500 i.u. of subcutaneous calcium heparin twice daily prevented DVT in the test group. An increase of soluble fibrin monomer complexes (SFMC) and fibrinogen in the plasma of patients with DVT suggested that the patients were hypercoagulable. No correlation between AT III values and DVT was observed. In the second trial, the effect of the same dose of heparin was compared with a twice daily s.c. injection of 5,000 U of a semi-synthetic heparin analogue (SSHA). The incidence of DVT was reduced to 15% by heparin; in the patients given SSHA the incidence was 25%, which was not significantly different from the heparin-treated group.
接受体外照射与阴道内镭疗联合治疗的妇科癌症患者参与了两项随机、对照、前瞻性试验。在第一项试验中，通过¹²⁵I-纤维蛋白原试验诊断出的对照组深静脉血栓形成（DVT）发生率为43%。试验组每日两次皮下注射7500国际单位的钙肝素可预防DVT。DVT患者血浆中可溶性纤维蛋白单体复合物（SFMC）和纤维蛋白原增加，提示患者存在高凝状态。未观察到抗凝血酶III（AT III）值与DVT之间的相关性。在第二项试验中，将相同剂量肝素的效果与每日两次皮下注射5000单位半合成肝素类似物（SSHA）的效果进行了比较。肝素使DVT发生率降至15%；接受SSHA治疗的患者中，发生率为25%，与肝素治疗组无显著差异。
